Select a medication above to begin.
Rybelsus
semaglutide
Black Box Warnings .
Thyroid C-cell Tumor Risk
contraindicated in pts w/ medullary thyroid carcinoma (MTC) hx or family hx, or in pts w/ multiple endocrine neoplasia syndrome type 2 (MEN 2); dose-related and duration-dependent incr. in thyroid C-cell tumor incidence observed in rodents, but human relevance unknown; uncertain value of routine serum calcitonin or thyroid ultrasound monitoring; advise pts of potential MTC risk and thyroid tumor sx (e.g., neck mass, dysphagia, dyspnea, persistent hoarseness)
Adult Dosing .
Dosage forms: TAB: 3 mg, 7 mg, 14 mg
diabetes mellitus, type 2
- [7-14 mg PO qd]
- Start: 3 mg PO qd x30 days, then incr. dose to 7 mg PO qd; Info: may incr. dose to 14 mg PO qd after at least 30 days on 7 mg PO qd if additional glycemic control needed; give w/ <4 oz water, 30min before 1st food/drink/med; do not cut/crush/chew tab
renal dosing
- [see below]
- renal impairment: no adjustment
- HD/PD: not defined
hepatic dosing
- [no adjustment]
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.